Trips Agreement Compulsory Licensing

In accordance with Article 31(f) of the TRIPS Agreement, products manufactured under compulsory licences must be manufactured primarily for the supply of the internal market. This applies to countries that can manufacture medicines, it limits the amount they can export when the medicine is manufactured under compulsory licence. And it has an impact on countries that can`t produce drugs and therefore want to import generic drugs. They would find it difficult to find countries capable of supplying them with medicines manufactured under compulsory license. Descriptive analyses were used to represent the difference between two groups, including the group tried by CL and the group not attempted by cl. In particular, the chi-square test or Fisher`s exact test for categorical variates and the t-test for continuous variates were performed to check whether the variables concerned were different from the groups. Next, two multivariate logistic regressions were conducted to shed light on the factors affecting the compulsory licensing attempt. Interesting variables such as region, population, incomes and communities were added to the model to adapt the macrocontext. Population and income were used after the log transformation to normalize the distribution. The PIPP index was then added to answer our research questions.

In addition, we performed additional analyses in which we assigned weights to income level variables to reflect the actual situation. Data management and analysis was carried out with the statistical software R (version 3.4.1). Significance was taken into account for p-values below 0.05. (b) Each member shall have the right to issue compulsory licences and the freedom to determine the grounds for the issue of such licences. – As a general rule, the person or company applying for a licence must have attempted, within a reasonable period of time, to negotiate a voluntary licence with the patent holder on reasonable commercial terms. Only in the event of failure can a compulsory licence be issued and, even if a compulsory licence has been granted, the patent holder must receive payment; The TRIPS Agreement provides that `the rightholder shall, in the circumstances of each case, enjoy equitable remuneration taking into account the economic value of the authorisation`, but does not define `reasonable remuneration` or `economic value`. Gorik Ooms and Johanna Hanefeld argue that low- and middle-income countries could improve access to medicines by forming an alliance to cred credeially threaten companies with mcCabe KW compulsory licenses. The revision of Article 27 of the TRIPS Agreement in January 1999: divergent views between industrialised and developing countries on the patentability of biotechnology. J Intell Prop L. 1998;6:41.

Figure 1 (Section 2) shows that, in the absence of voluntary licensing agreements and generic medicines readily available for imports, the system referred to in paragraph 6 may be the only option for countries without or with insufficient manufacturing capacity. Given the restrictions imposed on the Article 6 system and the fact that most medicines invented after 2005 in India are protected by patents, we can conclude that in the current ceteris paribus international IPR system, compulsory licensing is likely to play a more limited role in the future. . . .

Comments are closed.